SNT-3010912

SNT-3010912 is an investigational drug candidate within the pipeline of Sonata Therapeutics, a biotechnology company specializing in the development of Network Medicines. Sonata's platform is designed to identify Network Mediators—extracellular signaling proteins that coordinate the behavior of multiple cell types within a disease microenvironment, such as the tumor microenvironment or fibrotic tissue. By targeting these mediators, the company aims to develop therapies that can fundamentally reprogram the microenvironment to treat complex diseases. While SNT-3010912 is recognized as part of Sonata's development portfolio, specific details regarding its molecular target, mechanism of action, and precise therapeutic indication have not been publicly disclosed. The candidate may belong to one of several modalities utilized by the company, including small molecules, mRNA-based therapies, or cytokines.